Skip to content

NASDAQ · mid · thesis board

AKRO Akero Therapeutics

FGF21 analog (efruxifermin)

View race

Thesis

Editorial summary — not a primary filing

Efruxifermin FGF21 analog Phase 3; histology outcomes are the gate.

Next gate

2026-10-25Company-guidedPh3 readout

Phase 3 histology

73 days · Company: Company guidance

Survive-to-Event

ok

Cash covers the next gate with ~16 months spare (curated estimate).

Unverified estimate — not from a live SEC parse

Cash runway (~565d)100%
Days to gate (73d)13%
Show math

$780M cash ÷ $42M/mo burn ≈ 565 days. Source: curated SEC quarter figures.

Cash $780M as of 2026-03-31 (SEC)

Pipeline spine

  1. Preclinical
  2. Ph1
  3. Ph2
  4. Ph3
  5. Filed
  6. Approved

Rivals in this race

Open race →
MDGLApprovedokVKTXPh2okGILDPh2ok

Risks

  • Phase 3 histology bar
  • Tolerability
  • Capital for launch
  • Incumbent Rezdiffra

Source trail

  1. SECCash from latest reported quarter (curated)as of 2026-03-31
  2. ClinicalTrials.govNCT05039450as of 2026-07-01
  3. CompanyIR / press disclosuresas of 2026-07-01